140 related articles for article (PubMed ID: 2889256)
1. Famotidine: postmarketing clinical experience.
Saigenji K; Fukutomi H; Nakazawa S
Scand J Gastroenterol Suppl; 1987; 134():34-40. PubMed ID: 2889256
[TBL] [Abstract][Full Text] [Related]
2. Treatment of upper gastro-intestinal bleeding with the H2-receptor antagonist famotidine.
Aoki T
J Int Med Res; 1989; 17 Suppl 1():32A-40A. PubMed ID: 2566542
[TBL] [Abstract][Full Text] [Related]
3. Famotidine: clinical applications of a new H2-receptor antagonist. May 16, 1986, Carmel, California.
Am J Med; 1986 Oct; 81(4B):1-64. PubMed ID: 2877568
[No Abstract] [Full Text] [Related]
4. Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.
Langtry HD; Grant SM; Goa KL
Drugs; 1989 Oct; 38(4):551-90. PubMed ID: 2573505
[TBL] [Abstract][Full Text] [Related]
5. Review of an extensive worldwide study of a new H2-receptor antagonist, famotidine, as compared to ranitidine in the treatment of acute duodenal ulcer.
Bianchi Porro G; Dicenta C; Cook T; Humphries TJ
J Clin Gastroenterol; 1987; 9 Suppl 2():14-8. PubMed ID: 2887613
[TBL] [Abstract][Full Text] [Related]
6. Clinical benefits of intravenously administered famotidine in the treatment of upper gastrointestinal hemorrhage caused by peptic ulcer and stress ulcer disease.
Aoki T
Scand J Gastroenterol Suppl; 1987; 134():41-5. PubMed ID: 2889257
[TBL] [Abstract][Full Text] [Related]
7. Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome.
Campoli-Richards DM; Clissold SP
Drugs; 1986 Sep; 32(3):197-221. PubMed ID: 2875864
[TBL] [Abstract][Full Text] [Related]
8. Comparison of adjuvant therapies by an H2-receptor antagonist and a proton pump inhibitor after endoscopic treatment in hemostatic management of bleeding gastroduodenal ulcers.
Sakurada T; Kawashima J; Ariyama S; Kani K; Takabayashi H; Ohno S; Kato S; Yakabi K
Dig Endosc; 2012 Mar; 24(2):93-9. PubMed ID: 22348833
[TBL] [Abstract][Full Text] [Related]
9. Similar Efficacy of Proton-Pump Inhibitors vs H2-Receptor Antagonists in Reducing Risk of Upper Gastrointestinal Bleeding or Ulcers in High-Risk Users of Low-Dose Aspirin.
Chan FK; Kyaw M; Tanigawa T; Higuchi K; Fujimoto K; Cheong PK; Lee V; Kinoshita Y; Naito Y; Watanabe T; Ching JY; Lam K; Lo A; Chan H; Lui R; Tang RS; Sakata Y; Tse YK; Takeuchi T; Handa O; Nebiki H; Wu JC; Abe T; Mishiro T; Ng SC; Arakawa T
Gastroenterology; 2017 Jan; 152(1):105-110.e1. PubMed ID: 27641510
[TBL] [Abstract][Full Text] [Related]
10. Effect of a new H2-blocker, famotidine, in reflux esophagitis among severely handicapped children.
Miyake S; Yamada M; Iwamoto H; Yamashita S; Sugio Y
Clin Ther; 1987; 9(5):548-58. PubMed ID: 2889529
[TBL] [Abstract][Full Text] [Related]
11. Famotidine: a further development in the modern treatment of peptic ulcer disease. Proceedings of a satellite symposium of the XIIth International Congress of Gastroenterology. Lisbon, September 19, 1984.
Digestion; 1985; 32 Suppl 1():1-72. PubMed ID: 2866131
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of famotidine in the management of benign gastric ulcers.
Lyon DT
Am J Med; 1986 Oct; 81(4B):33-41. PubMed ID: 2877573
[TBL] [Abstract][Full Text] [Related]
13. Famotidine therapy for active duodenal ulcers. A multivariate analysis of factors affecting early healing.
Reynolds JC
Ann Intern Med; 1989 Jul; 111(1):7-14. PubMed ID: 2567589
[TBL] [Abstract][Full Text] [Related]
14. Suppression of nocturnal acid secretion with famotidine accelerates gastric ulcer healing.
McCullough AJ; Graham DY; Knuff TE; Lanza FL; Levenson HL; Lyon DT; Munsell WP; Perozza J; Roufail WM; Sinar DR
Gastroenterology; 1989 Oct; 97(4):860-6. PubMed ID: 2570730
[TBL] [Abstract][Full Text] [Related]
15. [Effect and safety of famotidine for therapy of gastrointestinal bleeding in children].
Chen FB; Huang XL; Chen J; Wu M; Wang J; Zhou X
Zhonghua Er Ke Za Zhi; 2005 Jan; 43(1):64-5. PubMed ID: 15796817
[No Abstract] [Full Text] [Related]
16. Stress ulcer prophylaxis in critically ill patients: a randomized controlled trial.
Kantorova I; Svoboda P; Scheer P; Doubek J; Rehorkova D; Bosakova H; Ochmann J
Hepatogastroenterology; 2004; 51(57):757-61. PubMed ID: 15143910
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of gastrosidine (famotidine) in the treatment of gastroesophageal reflux at the reflux esophagitis stage].
Vasil'ev IuV; Li IA
Eksp Klin Gastroenterol; 2002; (4):30-3, 131. PubMed ID: 12503271
[TBL] [Abstract][Full Text] [Related]
18. Famotidine in the treatment of gastritis.
Miwa T; Miyoshi A
Scand J Gastroenterol Suppl; 1987; 134():46-50. PubMed ID: 2889258
[TBL] [Abstract][Full Text] [Related]
19. Clinical importance of the new H2-antagonists.
Walt RP
Methods Find Exp Clin Pharmacol; 1989; 11 Suppl 1():97-9. PubMed ID: 2566730
[TBL] [Abstract][Full Text] [Related]
20. The tolerability and safety profile of famotidine.
Howden CW; Tytgat GN
Clin Ther; 1996; 18(1):36-54; discussion 35. PubMed ID: 8851452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
